61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199
Publication
, Conference
Graff, JN; Tagawa, S; Hoimes, C; Gerritsen, W; Vaishampayan, UN; Elliott, T; Hwang, C; Tije, AJT; Omlin, AG; McDermott, RS; De Wit, R; Qiu, P ...
Published in: Annals of Oncology
September 2021
Duke Scholars
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2021
Volume
32
Start / End Page
S383 / S383
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Graff, J. N., Tagawa, S., Hoimes, C., Gerritsen, W., Vaishampayan, U. N., Elliott, T., … Antonarakis, E. S. (2021). 61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199. In Annals of Oncology (Vol. 32, pp. S383–S383). Elsevier BV. https://doi.org/10.1016/j.annonc.2021.08.341
Graff, J. N., S. Tagawa, C. Hoimes, W. Gerritsen, U. N. Vaishampayan, T. Elliott, C. Hwang, et al. “61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199.” In Annals of Oncology, 32:S383–S383. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.341.
Graff JN, Tagawa S, Hoimes C, Gerritsen W, Vaishampayan UN, Elliott T, et al. 61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199. In: Annals of Oncology. Elsevier BV; 2021. p. S383–S383.
Graff, J. N., et al. “61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199.” Annals of Oncology, vol. 32, Elsevier BV, 2021, pp. S383–S383. Crossref, doi:10.1016/j.annonc.2021.08.341.
Graff JN, Tagawa S, Hoimes C, Gerritsen W, Vaishampayan UN, Elliott T, Hwang C, Tije AJT, Omlin AG, McDermott RS, De Wit R, Qiu P, Poehlein C, Kim J, Suttner L, Cristescu R, Marton MJ, Schloss C, de Bono JS, Antonarakis ES. 61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199. Annals of Oncology. Elsevier BV; 2021. p. S383–S383.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2021
Volume
32
Start / End Page
S383 / S383
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis